Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefaclor

FDA-approved product (capsule, oral), marketed as Ceclor, Ceclor Cd, Cefaclor and 1 more.

Registered studies
11
Lab records
32
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefaclor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Infection
  • Otitis media
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sprain
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Second-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC04

Repurposing investigation

Cefaclor is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli81.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae88.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

11registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 10 of 15 lab records
  • E. coli: measured active in 10 of 11 lab records
  • K. pneumoniae: measured active in 5 of 6 lab records
Open Cefaclor in ChEMBL Registered studies below
Show the 32 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefaclor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

    NCT06406114 · start 2025-05-05

    Registered record
    Registry ID
    NCT06406114
    Conditions
    Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
    Interventions
    Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge; Amoxicillin double-blind placebo-controlled drug challenge
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy +3 more
    InterventionBeta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge +1 more
    PhasePhase 2
    Registry statusRecruiting

  • LED Therapy for Third Molar Surgery

    NCT06640439 · start 2024-10-14

    Registered record
    Registry ID
    NCT06640439
    Conditions
    Molar, Third; Photobiomodulation; Photobiomodulation Therapy; Third Molar Surgery
    Interventions
    photobiomodulation; Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2024-10-14
    Completion
    2025-04-14
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMolar, Third; Photobiomodulation; Photobiomodulation Therapy; Third Molar Surgery
    Interventionphotobiomodulation; Antibiotic
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

    NCT05925309 · start 2023-07-01

    Registered record
    Registry ID
    NCT05925309
    Conditions
    Biliary Atresia; Cholangitis; Anti-Bacterial Agents
    Interventions
    Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem; Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2029-12-31
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Atresia; Cholangitis; Anti-Bacterial Agents
    InterventionBasic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem; Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
    PhaseNot applicable
    Registry statusRecruiting

  • Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

    NCT05398679 · start 2022-08-17

    Registered record
    Registry ID
    NCT05398679
    Conditions
    Endocarditis Infective
    Interventions
    Cefaclor; Ciprofloxacin Tablets; Ciprofloxacin Injection; Clindamycin Oral Capsule; Clindamycin Injection; Dicloxacillin Oral Capsule; Dicloxacillin; Fusidic Acid Only Product in Oral Dose Form; Fusidic Acid Only Product in Parenteral Dose Form; Levofloxacin Oral Tablet; Levofloxacin Injection; Linezolid Oral Tablet; Linezolid Injectable Product; Moxifloxacin tablet; Moxifloxacin Injectable Product; Rifampicin Only Product in Oral Dose Form; Rifampicin Only Product in Parenteral Dose Form; Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]; Sulfamethoxazole / Trimethoprim Injectable Product; Tedizolid Oral Tablet; Tedizolid Injection; Amoxicillin Capsules; Amoxicillin; Cefaclor Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-08-17
    Completion
    2027-12-30
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis Infective
    InterventionCefaclor; Ciprofloxacin Tablets; Ciprofloxacin Injection; Clindamycin Oral Capsule +20 more
    PhasePhase 4
    Registry statusRecruiting

  • Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?

    NCT02490293 · start 2015-06

    Registered record
    Registry ID
    NCT02490293
    Conditions
    Acute Cholecystitis
    Interventions
    Cephalosporin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-06
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Cholecystitis
    InterventionCephalosporin; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • The Effects of Antibiotic Combinations on Stem Cells

    NCT04713436 · start 2014-01-01

    Registered record
    Registry ID
    NCT04713436
    Conditions
    Stem Cells; Anti-Bacterial Agents
    Interventions
    Differentiation Markers
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-01-01
    Completion
    2017-02-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStem Cells; Anti-Bacterial Agents
    InterventionDifferentiation Markers
    PhaseNot recorded
    Registry statusCompleted

  • Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use

    NCT01561703 · start 2012-03

    Registered record
    Registry ID
    NCT01561703
    Conditions
    Snoring; Strep Throat
    Interventions
    Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-03
    Completion
    2015-06
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSnoring; Strep Throat
    InterventionAntibiotic
    PhaseNot applicable
    Registry statusCompleted

  • Use of Antibacterial Cement in Infected Dentin

    NCT01449136 · start 2008-01

    Registered record
    Registry ID
    NCT01449136
    Conditions
    Dental Caries
    Interventions
    Antibacterial cement
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDental Caries
    InterventionAntibacterial cement
    PhaseNot applicable
    Registry statusCompleted

  • German Corneal Cross Linking Register

    NCT00560651 · start 2007-11

    Registered record
    Registry ID
    NCT00560651
    Conditions
    Keratoconus
    Interventions
    CCL (Corneal Cross Linking)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2007-11
    Completion
    2027-11
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratoconus
    InterventionCCL (Corneal Cross Linking)
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria

    NCT00257140 · start 1931-06

    Registered record
    Registry ID
    NCT00257140
    Conditions
    Bronchitis; Bronchitis, Chronic
    Interventions
    levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    1931-06
    Completion
    1994-07
    Enrolment
    367

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis; Bronchitis, Chronic
    Interventionlevofloxacin
    PhasePhase 2 / Phase 3
    Registry statusCompleted